跳至主要内容
临床试验/ACTRN12623000898651
ACTRN12623000898651进行中(未招募)Unknown

Feasibility and pilot randomised controlled trial of a co-designed home-based personalised reablement strategy program delivered via Voice-Controlled Intelligent Personal Assistants in older adults aged 60-89 years with mild cognitive impairment and/or dementia.

Dementia Australia Research Foundation0 个研究点目标入组 30 人开始时间: 2023年8月22日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
60 Years 至 89 Years(—)
性别
All

入选标准

  • Prospective participants must meet the following criteria including English-speaking, aged 60-89 years, reside anywhere in Australia, have a recent (less than 6 months) clinical diagnosis of early dementia (any type) or MCI by a Cognitive, Dementia and Memory Service (CDAMS) Clinic, Neuropsychologist or General Practitioner; have a home Wi-Fi network and smart devices and have a primary carer with at least 50% close contact during the 12-week period.

排除标准

  • Participants will be ineligible if they report currently being unable to walk across a room unaided; are non-English speaking or have difficulty communicating with study personnel or a VIPA device due to speech or hearing problems; unwilling to be randomised; planning to be away from the VIPA device is greater than 4 weeks during the 12-week intervention period; any disorder of such severity that life expectancy is less than 12 months, or any cognitive or physical impairment or disability that in the opinion of the study investigators would result in the participant having difficulty interacting with Buddy Link or performing personalized reablement program safely. These include
  • - Progressive neurological disorders including Parkinson’s Disease and multiple sclerosis;
  • - Schizophrenia, other psychotic disorders, bipolar disorder;
  • - Severe knee or hip arthritis that would interfere with ability to complete functional tests and the intervention;
  • - Lung disease requiring regular use of supplemental oxygen
  • - Renal disease requiring dialysis;
  • - Hyper- or hypothyroidism;
  • - Cardiovascular disease (including New York Heart Association (NYHA) Class III or IV congestive heart failure, clinically significant valvular disease, history of cardiac arrest, presence of an implantable cardiac defibrillator, or uncontrolled angina)
  • - Other disorder of such severity that life expectancy is less than 12 months;
  • - Stroke, hip or knee replacement, spinal surgery, myocardial infarction or major heart surgery in the past 6 months.

研究者

发起方
Dementia Australia Research Foundation

相似试验

Feasibility and pilot randomised controlled trial of... | 临床试验